Mutation detection assay
View Patent ↗A method of sample analysis is provided. In certain embodiments, the method involves: a) amplifying a product from a sample that comprises both wild type copies of a genomic locus and mutant copies of the genomic locus that have a point mutation relative to said wild type copies of the genomic locus, to produce an amplified sample, where: i. the amplifying is done using a first primer and a second primer; and ii. the first primer comprises a 3′ terminal nucleotide that base pairs with the point mutation and also comprises a nucleotide sequence that is fully complementary to a sequence in the locus with the exception of a single base mismatch within 6 bases of the 3′ terminal nucleotide; and b) detecting the presence of said product in said amplified sample using a flap assay that employs an invasive oligonucleotide. A kit for performing the method is also provided.
1. A kit for detecting mutant copies of a locus in human genomic DNA, comprising:
a) PCR reagents that include a first primer and a second primer, wherein said first primer comprises a 3′ terminal nucleotide that base pairs with a point mutation in said locus in human genomic DNA and also comprises a nucleotide sequence that is fully complementary to a sequence in said locus with the exception of a single base mismatch within 6 bases of said 3′ terminal nucleotide; and
b) flap assay reagents that include a flap endonuclease, a FRET cassette and a flap oligonucleotide that comprises a nucleotide that base pairs with said point mutation,
wherein the kit does not comprise an invasive oligonucleotide that is distinct from said first primer and wherein the PCR reagents and flap assay reagents are selected to effect amplification and detection of mutant copies of said locus when they are combined with a nucleic acid sample that comprises wild type and mutant copies of said genomic locus and subjected to thermocycling.
2. The kit of claim 1 , wherein said kit further comprises PCR and flap reagents for amplification and detection of a control nucleic acid.
3. The kit of claim 2 , further comprising instructions for using the PCR reagents and the flap assay reagents to detect mutant copies of said genomic locus in a nucleic acid sample.
4. The kit of claim 1 , wherein said mismatch in said first primer is at position −1, position −2, position −3, position −4 or position −5 relative to said 3′ terminal nucleotide.
5. The kit of claim 1 , wherein said kit is capable of detecting mutant copies of said locus in a nucleic acid sample that contains at least 10 times more wild type copies of said genomic locus than mutant copies of said genomic locus.
6. The kit of claim 5 , wherein said kit is capable of detecting mutant copies of said locus in a nucleic acid sample that contains at least 100 times more wild type copies of said genomic locus than mutant copies of said genomic locus.
7. The kit of claim 6 , wherein said kit is capable of detecting mutant copies of said locus in a nucleic acid sample that contains at least 1,000 times more wild type copies of said genomic locus than mutant copies of said genomic locus.
8. The kit of claim 1 , wherein the mutation of said genomic locus is associated with a disease.
9. The kit of claim 8 , wherein the mutation of said genomic locus is associated with cancer.
10. The kit of claim 9 , wherein the mutation of said genomic locus is associated with one or more cancers selected from the group consisting of: breast cancer, melanoma, renal cancer, endometrial cancer, ovarian cancer, pancreatic cancer, leukemia, colorectal cancer, prostate cancer, mesothelioma, glioma, medullobastoma, polycythemia, lymphoma, sarcoma and multiple myeloma.
11. The kit of claim 9 , wherein the mutation is in a gene selected from the group consisting of: PIK3CA, NRAS, KRAS, JAK2, HRAS, FGFR3, FGFR1, EGFR, CDK4, BRAF, RET, PGDFRA, KIT and ERBB2.
12. The kit of claim 9 , wherein said genomic locus is the KRAS gene.
13. The kit of claim 9 , wherein said genomic locus is the BRAF gene.
14. The kit of claim 1 , wherein the mutation of said target locus is used to diagnose a disease or predict a response to treatment.
15. The kit of claim 1 , wherein said kit further comprises PCR reagents and assay reagents for amplifying and detecting a point mutation in a second genomic locus of said human genomic DNA.
16. The kit of claim 1 , wherein said FRET cassette comprises a fluorophore selected from the group consisting of 6-carboxyfluorescein (FAM), Redmond Red, Yakima Yellow, and Quasor670.
17. The kit of claim 1 , wherein the kit comprises a thermostable polymerase and nucleotides.
18. The kit of claim 1 , wherein the first primer, second primer, flap endonuclease, FRET cassette and flap oligonucleotide are present in separate containers.